These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 23006049

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High resolution multimer analysis and the PFA-100 platelet function analyser can detect von Willebrand disease type 2A without a pathological ratio of ristocetin cofactor activity and von Willebrand antigen level.
    Weiss DR, Strasser EF, Ringwald J, Zimmermann R, Eckstein R.
    Clin Lab; 2012; 58(11-12):1203-9. PubMed ID: 23289190
    [Abstract] [Full Text] [Related]

  • 7. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA, Mancuso DJ, Evan Sadler J, Ponder JW, Jozwiak MA, Christopherson PA, Cox Gill J, Paul Scott J, Montgomery RR.
    Blood; 1998 Mar 01; 91(5):1572-81. PubMed ID: 9473222
    [Abstract] [Full Text] [Related]

  • 8. Diagnosis or Exclusion of von Willebrand Disease Using Laboratory Testing.
    Favaloro EJ.
    Methods Mol Biol; 2017 Mar 01; 1646():391-402. PubMed ID: 28804843
    [Abstract] [Full Text] [Related]

  • 9. von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.
    Miller JL, Kupinski JM, Castella A, Ruggeri ZM.
    J Clin Invest; 1983 Nov 01; 72(5):1532-42. PubMed ID: 6415113
    [Abstract] [Full Text] [Related]

  • 10. Laboratory Testing for von Willebrand Factor Activity by Glycoprotein Ib Binding Assays (VWF:GPIb).
    Patzke J, Favaloro EJ.
    Methods Mol Biol; 2017 Nov 01; 1646():453-460. PubMed ID: 28804847
    [Abstract] [Full Text] [Related]

  • 11. Clinically relevant differences between assays for von Willebrand factor activity.
    Boender J, Eikenboom J, van der Bom JG, Meijer K, de Meris J, Fijnvandraat K, Cnossen MH, Laros-van Gorkom BAP, van Heerde WL, Mauser-Bunschoten EP, de Maat MPM, Leebeek FWG, WiN Study Group.
    J Thromb Haemost; 2018 Dec 01; 16(12):2413-2424. PubMed ID: 30358069
    [Abstract] [Full Text] [Related]

  • 12. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A, Sartorello F, Pontara E, Gallinaro L, Bertomoro A, Grazia Cattini M, Daidone V, Szukowska M, Pagnan A.
    Thromb Haemost; 2007 Dec 01; 98(6):1182-7. PubMed ID: 18064311
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination.
    Stufano F, Baronciani L, Pagliari MT, Franchi F, Cozzi G, Garcia-Oya I, Bucciarelli P, Boscarino M, Peyvandi F.
    J Thromb Haemost; 2015 Oct 01; 13(10):1806-14. PubMed ID: 26206100
    [Abstract] [Full Text] [Related]

  • 14. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
    Casonato A, Pontara E, Sartorello F, Bertomoro A, Durante C, Girolami A.
    J Lab Clin Med; 2001 Jan 01; 137(1):70-6. PubMed ID: 11150026
    [Abstract] [Full Text] [Related]

  • 15. Platelet thrombus formation on collagen at high shear rates is mediated by von Willebrand factor-glycoprotein Ib interaction and inhibited by von Willebrand factor-glycoprotein IIb/IIIa interaction.
    Wu YP, Vink T, Schiphorst M, van Zanten GH, IJsseldijk MJ, de Groot PG, Sixma JJ.
    Arterioscler Thromb Vasc Biol; 2000 Jun 01; 20(6):1661-7. PubMed ID: 10845886
    [Abstract] [Full Text] [Related]

  • 16. A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function.
    Casonato A, Cattini MG, Soldera C, Marcato S, Sartorello F, Pontara E, Pagnan A.
    J Lab Clin Med; 2004 Nov 01; 144(5):254-9. PubMed ID: 15570243
    [Abstract] [Full Text] [Related]

  • 17. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL, Siekmann J, Schwarz HP.
    Semin Thromb Hemost; 2002 Apr 01; 28(2):149-60. PubMed ID: 11992238
    [Abstract] [Full Text] [Related]

  • 18. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
    Caron C, Hilbert L, Vanhoorelbeke K, Deckmyn H, Goudemand J, Mazurier C.
    Br J Haematol; 2006 Jun 01; 133(6):655-63. PubMed ID: 16704443
    [Abstract] [Full Text] [Related]

  • 19. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
    Casonato A, Pontara E, Bertomoro A, Sartorello F, Cattini MG, Girolami A.
    Br J Haematol; 2001 Mar 01; 112(3):578-83. PubMed ID: 11260057
    [Abstract] [Full Text] [Related]

  • 20. A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease.
    Stepanian A, Ribba AS, Lavergne JM, Fressinaud E, Juhan-Vague I, Mazurier C, Girma JP, Meyer D.
    Br J Haematol; 2003 Feb 01; 120(4):643-51. PubMed ID: 12588351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.